Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine Prescribed for COVID-19

    June 2020 in “ The Journal of Allergy and Clinical Immunology In Practice ”
    Jérémie Delaleu, Benjamin Deniau, Maxime Battistella, Adèle de Masson, Benoît Bensaïd, M. Jachiet, Ingrid Lazaridou, M. Bagot, Jean‐David Bouaziz, Gordon L. Archer, Anne Bergeron, Anne Bergeron, Louise Bondeelle, Jean‐David Bouaziz, D. Bouda, David Boutboul, Berthon I. Brindel, Emmanuelle Bugnet, S. Caillat Zucman, S. Cassonnet, Karine Celli Lebras, Jacqueline Chabert, Sylvie Chevret, Meredith Edwards, Claire Davoine, Nathalie De Castro, É. de Kerviler, Constance de Margerie‐Mellon, Constance Delaugerre, François Dépret, B. Denis, Lalia Djaghout, Clarisse Dupin, Dominique Farge, Catherine Fauvaux, E. Feredj, Delphine Feyeux, Jean‐Sébastien Fontaine, Véronique Frémeaux‐Bacchi, Lionel Galicier, Stéphanie Harel, Jegu AL, E. Kozakiewicz, Marc Lebel, Ariane Baye, Jennifer Goff, Pierre Le Guen, Nicolas Etienne, Geoffroy Liégeon, Gwenaël Lorillon, I. Madelaine Chambrin, G. Martin de Frémont, Marie Meunier, Jean‐Michel Molina, Florence Morin, Éric Oksenhendler, Régis Peffault de Latour, Olivier Peyrony, Benoît Plaud, Maud Salmona, Julien Saussereau, Juliette Soret
    TLDR A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.
    A 76-year-old male with diabetes developed acute generalized exanthematous pustulosis (AGEP) after 9 days of hydroxychloroquine (HCQ) treatment for COVID-19, which was confirmed by histological examination. The pustular eruption covered 30% of his body. Despite stopping HCQ, the patient died from a massive pulmonary embolism. The study underscored the importance of monitoring for severe skin side effects of HCQ, particularly when used off-label for COVID-19.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 10 results

    Related Research

    1 / 1 results